Carbonic anhydrase II

From WikiMD's WELLNESSPEDIA

Carbonic anhydrase II (CA II) is an enzyme that belongs to the family of carbonic anhydrases, which are zinc-containing metalloenzymes. These enzymes catalyze the reversible hydration of carbon dioxide, a crucial reaction in many physiological processes.

Structure[edit]

Carbonic anhydrase II is a monomeric protein with a molecular weight of approximately 29 kDa. It is characterized by a single zinc ion in its active site, which is essential for its enzymatic activity. The enzyme's structure is highly conserved across different species, reflecting its fundamental role in biological systems.

Function[edit]

CA II is one of the most active carbonic anhydrases and is found in high concentrations in red blood cells, kidneys, and the gastrointestinal tract. It facilitates the rapid conversion of carbon dioxide and water to bicarbonate and protons, a reaction that is vital for maintaining acid-base balance in tissues and organs.

Physiological Roles[edit]

  • Respiratory System: In the lungs, CA II helps convert bicarbonate back to carbon dioxide for exhalation.
  • Renal System: In the kidneys, it plays a role in acid-base homeostasis by reabsorbing bicarbonate from urine.
  • Digestive System: In the stomach, it contributes to the production of gastric acid by providing protons.

Clinical Significance[edit]

Mutations in the gene encoding carbonic anhydrase II can lead to a rare genetic disorder known as osteopetrosis, which is characterized by increased bone density and other systemic symptoms. CA II deficiency can also result in renal tubular acidosis, a condition where the kidneys fail to acidify urine properly.

Inhibitors[edit]

Carbonic anhydrase inhibitors, such as acetazolamide, are used clinically to treat conditions like glaucoma, epilepsy, and altitude sickness. These inhibitors work by reducing the activity of CA II, thereby affecting fluid secretion and pH balance.

Research and Applications[edit]

CA II is a target for drug development due to its involvement in various diseases. Research is ongoing to develop more selective inhibitors that can modulate its activity without affecting other isoforms of carbonic anhydrase.

Also see[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.